Investigators compared the short-term surgical and long-term oncologic safety of robotic gastrectomy vs laparoscopic gastrectomy for patients with gastric cancer.
The nonrandomized, multicenter, multicohort, open-label, phase 1b/2 KEYNOTE-365 trial evaluated the safety, tolerability, and efficacy of pembrolizumab combination therapy in men with mCRPC.
CRFS after relugolix was not significantly different compared with leuprolide in men with advanced prostate cancer and metastatic disease.
ADT exposure after prostate cancer treatment is associated with the onset of dementia.
RT for prostate cancer is associated with distinct treatment-related complications such as cystitis and urinary stricture.
Treatment discontinuation from adverse events in real-world use is 32% higher for apalutamide and 49% higher for enzalutamide than reported in clinical trials of patients with non-metastatic castration-resistant prostate cancer.
Researchers sought to determine whether R-NPLD would be an effective therapy in older patients with DLBCL.
Researchers sought to determine whether orelabrutinib and MIL62 combination therapy would be safe and effective in patients with relapsed/refractory NHL.
The program includes 10 weeks of education and counseling with 5 modules and 3 months’ of follow-up.
Researchers sought to determine whether tafasitamab with lenalidomide would improve outcomes for patients with relapsed/refractory DLBCL.
